QFG: Alternate Controller Enabled Insulin Infusion Pump

Product code QFG, “Alternate Controller Enabled Insulin Infusion Pump” in FDA's classification database, is a Class II device type under 21 CFR 880.5730 (alternate controller enabled infusion pump), reviewed by FDA's Clinical Chemistry panel. FDA's 510(k) database lists 29 clearances under QFG, 29 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
QFG
Regulation
21 CFR 880.5730
Class
II
Panel
Clinical Chemistry
Clearances
29
Most recent
Sep 11, 2026
Median review, last 2 years
93 days
Third-party review
Not eligible
Implant
No

What it covers

An alternate controller enabled insulin infusion pump (ACE insulin pump) is a device intended for the infusion of insulin into a patient. The ACE insulin pump may include basal and bolus drug delivery at set or variable rates. ACE insulin pumps are designed to reliably and securely communicate with external devices, such as automated insulin dosing systems, to allow insulin delivery commands to be received, executed, and confirmed. ACE insulin pumps are intended to be used both alone and in conjunction with digitally connected medical devices for the purpose of insulin delivery.

FDA’s definition of product code QFG, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K260001Mint ACE PumpBeta Bionics, Inc.Sep 11, 2026Traditional
K261672twiist Automated Insulin Delivery (AID) SystemDeka Research and DevelopmentJun 17, 2026Special
K253976iLet ACE PumpBeta Bionics, Inc.Apr 30, 2026Traditional
K253743MiniMed Flex pumpMedtronic Minimed, Inc.Mar 12, 2026Traditional
K253470MiniMed 780G Insulin Pump (MMT-1884); MiniMed 780G Insulin Pump Kit (MMT-1894)Medtronic Minimed, Inc.Jan 15, 2026Traditional
K253074Tandem Mobi insulin pump with interoperable technologyTandem Diabetes Care, Inc.Nov 6, 2025Traditional
K252770iLet ACE PumpBeta Bionics, Inc.Sep 29, 2025Special
K250792t:slim X2 insulin pump with interoperable technologyTandem Diabetes Care, Inc.Sep 24, 2025Traditional
K251032MiniMed 780G insulin pumpMedtronic Minimed, Inc.Jul 1, 2025Traditional
K250930twiist systemDeka Research & Development Corp.Apr 2, 2025Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 29 with a free account)

Clearances by year

29 QFG 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)5108
2025544
2024589
20239150
20222435
2020130
2019298

Who submits

9 applicants cleared a QFG device since 2011. 93% of the clearances went to applicants in United States, then Germany (3%) and Israel (3%). By type: Traditional 72%, Special 24% and Direct 3%.

ApplicantClearances since 2011
Tandem Diabetes Care, Inc.10
Beta Bionics, Inc.5
Deka Research and Development4
Insulet Corporation3
Medtronic Minimed, Inc.3
Deka Research & Development Corp.1
Embecta Medical I, LLC1
Roche Diabetes Care GmbH1

How FDA classifies it

Class II (special controls). The special controls for this device are:

(1) Design verification and validation must include the following:

(i) Evidence demonstrating that device infusion delivery accuracy conforms to defined user needs and intended uses and is validated to support safe use under actual use conditions.

(A) Design input requirements must include delivery accuracy specifications under reasonably foreseeable use conditions, including ambient temperature changes, pressure changes (e.g., head-height, backpressure, atmospheric), and, as appropriate, different drug fluidic properties.

(B) Test results must demonstrate that the device meets the design input requirements for delivery accuracy under use conditions for the programmable range of delivery rates and volumes. Testing shall be conducted with a statistically valid number of devices to account for variation between devices.

(ii) Validation testing results demonstrating the ability of the pump to detect relevant hazards associated with drug delivery and the route of administration (e.g., occlusions, air in line, etc.) within a clinically relevant timeframe across the range of programmable drug delivery rates and volumes. Hazard detection must be appropriate for the intended use of the device and testing must validate appropriate performance under the conditions of use for the device.

(iii) Validation testing results demonstrating compatibility with drugs that may be used with the pump based on its labeling. Testing must include assessment of drug stability under reasonably foreseeable use conditions that may affect drug stability (e.g., temperature, light exposure, or other factors as needed).

(iv) The device parts that directly or indirectly contact the patient must be demonstrated to be biocompatible. This shall include chemical and particulate characterization on the final, finished, fluid contacting device components demonstrating that risk of harm from device-related residues is reasonably low.

(v) Evidence verifying and validating that the device is reliable over the ACE pump use life, as specified in the design file, in terms of all device functions and in terms of pump performance.

(vi) The device must be designed and tested for electrical safety, electromagnetic compatibility, and radio frequency wireless safety and availability consistent with patient safety requirements in the intended use environment.

(vii) For any device that is capable of delivering more than one drug, the risk of cross-channeling drugs must be adequately mitigated.

(viii) For any devices intended for multiple patient use, testing must demonstrate validation of reprocessing procedures and include verification that the device meets all functional and performance requirements after reprocessing.

(2) Design verification and validation activities must include appropriate design inputs and design outputs that are essential for the proper functioning of the device that have been documented and include the following:

(i) Risk control measures shall be implemented to address device system hazards and the design decisions related to how the risk control measures impact essential performance shall be documented.

(ii) A traceability analysis demonstrating that all hazards are adequately controlled and that all controls have been validated in the final device design.

(3) The device shall include validated interface specifications for digitally connected devices. These interface specifications shall, at a minimum, provide for the following:

(i) Secure authentication (pairing) to external devices.

(ii) Secure, accurate, and reliable means of data transmission between the pump and connected devices.

(iii) Sharing of necessary state information between the pump and any digitally connected alternate controllers (e.g., battery level, reservoir level, pump status, error conditions).

(iv) Ensuring that the pump continues to operate safely when data is received in a manner outside the bounds of the parameters specified.

(v) A detailed process and procedure for sharing the pump interface specification with digitally connected devices and for validating the correct implementation of that protocol.

(4) The device must include appropriate measures to ensure that safe therapy is maintained when communications with digitally connected alternate controller devices is interrupted, lost, or re-established after an interruption (e.g., reverting to a pre-programmed, safe drug delivery rate). Validation testing results must demonstrate that critical events that occur during a loss of communications (e.g., commands, device malfunctions, occlusions, etc.) are handled appropriately during and after the interruption.

(5) The device design must ensure that a record of critical events is stored and accessible for an adequate period to allow for auditing of communications between digitally connected devices and to facilitate the sharing of pertinent information with the responsible parties for those connected devices. Critical events to be stored by the system must, at a minimum, include:

(i) A record of all drug delivery

(ii) Commands issued to the pump and pump confirmations

(iii) Device malfunctions

(iv) Alarms and alerts and associated acknowledgements

(v) Connectivity events (e.g., establishment or loss of communications)

(6) Design verification and validation must include results obtained through a human factors study that demonstrates that an intended user can safely use the device for its intended use.

(7) Device labeling must include the following:

(i) A prominent statement identifying the drugs that are compatible with the device, including the identity and concentration of those drugs as appropriate.

(ii) A description of the minimum and maximum basal rates, minimum and maximum bolus volumes, and the increment size for basal and bolus delivery, or other similarly applicable information about drug delivery parameters.

(iii) A description of the pump accuracy at minimum, intermediate, and maximum bolus delivery volumes and the method(s) used to establish bolus delivery accuracy. For each bolus volume, pump accuracy shall be described in terms of the number of bolus doses measured to be within a given range as compared to the commanded volume. An acceptable accuracy description (depending on the drug delivered and bolus volume) may be provided as follows for each bolus volume tested, as applicable: Number of bolus doses with volume that is <25 percent, 25 percent to <75 percent, 75 percent to <95 percent, 95 percent to <105 percent, 105 percent to <125 percent, 125 percent to <175 percent, 175 to 250 percent, and >250 percent of the commanded amount.

(iv) A description of the pump accuracy at minimum, intermediate, and maximum basal delivery rates and the method(s) used to establish basal delivery accuracy. For each basal rate, pump accuracy shall be described in terms of the amount of drug delivered after the basal delivery was first commanded, without a warmup period, up to various time points. The information provided must include typical pump performance, as well as worst-case pump performance observed during testing in terms of both over-delivery and under-delivery. An acceptable accuracy description (depending on the drug delivered) may be provided as follows, as applicable: The total volume delivered 1 hour, 6 hours, and 12 hours after starting delivery for a typical pump tested, as well as for the pump that delivered the least and the pump that delivered the most at each time point.

(v) A description of delivery hazard alarm performance, as applicable. For occlusion alarms, performance shall be reported at minimum, intermediate, and maximum delivery rates and volumes. This description must include the specification for the longest time period that may elapse before an occlusion alarm is triggered under each delivery condition, as well as the typical results observed during performance testing of the pumps.

(vi) For wireless connection enabled devices, a description of the wireless quality of service required for proper use of the device.

(vii) For any infusion pumps intended for multiple patient reuse, instructions for safely reprocessing the device between uses.

From 21 CFR 880.5730. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 880.5730 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QFG clearances declared.

Ask about QFG

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about QFG

What is FDA product code QFG?

Product code QFG, “Alternate Controller Enabled Insulin Infusion Pump” in FDA's classification database, is a Class II device type under 21 CFR 880.5730 (alternate controller enabled infusion pump), reviewed by FDA's Clinical Chemistry panel. FDA's 510(k) database lists 29 clearances under QFG, 29 of them since 2011.

How many 510(k) clearances are there under QFG?

FDA’s 510(k) database listed 29 clearances under QFG as of Oct 29, 2026, 29 of them decided since 2011; the most recent decision was Sep 11, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a QFG 510(k)?

For the 10 QFG clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 93 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most QFG clearances?

Since 2011: Tandem Diabetes Care, Inc. (10), Beta Bionics, Inc. (5), Deka Research and Development (4), Insulet Corporation (3) and Medtronic Minimed, Inc. (3). 9 applicants have cleared a QFG device in that time.

Sources

  1. FDA product classification: QFG · Product Classification database
  2. 21 CFR 880.5730: Alternate controller enabled infusion pump · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for QFG · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow QFGGet an email when FDA clears, recalls or publishes guidance for QFG devices.

Know what FDA already cleared.